FDA clears IND Application for OTP-01 in solid tumors
“I am proud of our Ottimo team for their remarkable speed in bringing OTP-01 into the clinic since coming out of stealth,” said David Epstein, Chair and Chief Executive Officer of Ottimo Pharma. “We are developing this unique, first-in-class antibody to be the ideal backbone therapy to combine with Antibody Drug Conjugates or chemotherapy, with the aim of creating a new standard of care across a wide range of solid tumors.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.